Get the Stockscreener App
118.77
0.15%
-0.18
After Hours:
118.77
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $118.77, with a volume of 2.17M.
It is down -0.15% in the last 24 hours and up +4.74% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$118.95
Open:
$118.71
24h Volume:
2.17M
Relative Volume:
0.48
Market Cap:
$206.00B
Revenue:
$41.22B
Net Income/Loss:
$5.77B
P/E Ratio:
40.40
EPS:
2.94
Net Cash Flow:
$6.49B
1W Performance:
+0.86%
1M Performance:
+4.74%
6M Performance:
+17.91%
1Y Performance:
+14.61%
1-Day Range:
$117.86
$119.19
1-Week Range:
$117.01
$120.53
52-Week Range:
$99.71
$121.64
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
118.77 | 206.00B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
392.15 | 149.49B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
90.66 | 133.62B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
86.54 | 110.97B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
71.35 | 42.08B | 6.60B | 4.16B | 490.10M | 6.93 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories (NYSE:ABT) Shares Sold by Captrust Financial Advisors - MarketBeat
Rockefeller Capital Management L.P. Decreases Stake in Abbott Laboratories (NYSE:ABT) - MarketBeat
Quantbot Technologies LP Sells 141,543 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott (ABT) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Abbott Laboratories stock outperforms competitors despite losses on the day - MarketWatch
Atlantic Union Bankshares Corp Sells 4,950 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Hantz Financial Services Inc. Has $33.26 Million Stock Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Northwest & Ethical Investments L.P. Acquires 12,842 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Cell Counting Market to Evolve at a Modest 6.8% CAGR through 2031 | SkyQuest Technology - Benzinga
The Zacks Analyst Blog Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Stock Holdings Lessened by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Public Sector Pension Investment Board Reduces Stock Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Has $80.97 Million Stock Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
BBR Partners LLC Boosts Stock Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
CreativeOne Wealth LLC Increases Stake in Abbott Laboratories (NYSE:ABT) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Purchases 57,049 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Fmr LLC Sells 598,841 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Protein Therapeutics Market May See a Big Move | Abbott Laboratories, Baxter, F. Hoffmann-La Roche - openPR
Loomis Sayles & Co. L P Has $11.30 Million Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Top Research Reports for Abbott, BlackRock & ConocoPhillips - Yahoo Finance
Infant Nutrition Market Detailed Industry Analysis and Key - openPR
BNP Paribas Decreases Stake in Abbott Laboratories (NYSE:ABT) - MarketBeat
Glenmede Trust Co. NA Has $172.94 Million Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Labs Stock Falls After Baby-Formula Ruling. Reckitt Benckiser Tumbles Too. - MSN
Abbott Laboratories (NYSE:ABT) Shares Sold by Bridgewater Associates LP - MarketBeat
Transamerica Financial Advisors Inc. Buys Shares of 6,302 Abbott Laboratories (NYSE:ABT) - MarketBeat
Unlocking Intrinsic Value: Analysis of Abbott Laboratories - GuruFocus.com
NEC Baby Formula Lawsuit - Lawsuit Information Center Blog
Judge denies Abbott request for retrial, lower damages in $500M baby formula case - Seeking Alpha
Abbott Laboratories (NYSE:ABT) Shares Bought by Prospector Partners LLC - MarketBeat
D.A. Davidson & CO. Has $17.70 Million Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Dai ichi Life Insurance Company Ltd Sells 10,563 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (XSGO:ABT) GF Value Rank : 6 (As of Nov. 26, 2024) - GuruFocus.com
The Manufacturers Life Insurance Company Decreases Stake in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Protein Supplements Market Global Forecast Report and - GlobeNewswire
Protein Supplements Market Global Forecast Report and Company Analysis 2025-2033 Featuring Abbott Laboratories, Herbalife, Nestle, Simply Good Foods, WK Kellogg, PepsiCo, and Glanbia - Yahoo Finance
Australia Diabetes Market Forecasts and Company Analysis 2024-2032, Novo Nordisk, Eli Lilly, Roche, Abbott Laboratories, Insuletn, Dexcom, Medtronic, Ypsomed - Yahoo Finance
Brown Brothers Harriman & Co. Decreases Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Dynamic Technology Lab Private Ltd Grows Stock Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Fisher Asset Management LLC Boosts Stake in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Launches AI-Guided Heart Valve System, Marks First Patient Procedures | ABT Stock News - StockTitan
Jennison Associates LLC Reduces Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Abbott Laboratories: Investors Should Wait For A Pullback (NYSE:ABT) - Seeking Alpha
Daiwa Securities Group Inc. Buys 23,834 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Capital Investment Counsel LLC Trims Stake in Abbott Laboratories (NYSE:ABT) - MarketBeat
Summit Trail Advisors LLC Buys 7,804 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) is largely controlled by institutional shareholders who own 78% of the company - Yahoo Finance
Meridian Wealth Management LLC Takes $2.03 Million Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):